| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
INSERM Unité 344 (H.F.-Y., R.F., K.P., E.M.)
Endocrinologie Moléculaire Faculté de Médecine
Necker Paris cedex 15, France 75730
Laboratoire de
Physiologie Générale et Comparée (FY.H., D.F.,
B.D., L.A.) Muséum National dHistoire
Naturelle UMR 8572 CNRS Paris cedex 05, France 75231
PRL and T3 are involved in
antagonistic regulations during various developmental processes in
vertebrate species. We have studied cross-talk between transcription
factors activated by these signaling pathways, i.e. signal
transducer and activator of transcription 5 (Stat5) and thyroid hormone
receptor ß1 (TRß1). Liganded TRß1 in the presence of its
heterodimeric partner, retinoid X receptor
(RXR
),
inhibited the PRL-induced Stat5a- and
Stat5b-dependent reporter gene expression by up to 60%. This
T3-inhibitory effect studied on Stat5 activity
was partly reversed by overexpression of a TRß1 dominant negative
variant mutated within its nuclear localization signal (TR2A). We next
showed that TRß1 and TR2A in the presence of RXR
increased and
decreased, respectively, Stat5 localization into the nucleus regardless
of hormonal stimulation. Thus, our data suggest that TRß1 can be
associated with Stat5 in the cytoplasm and may be involved in Stat5
nuclear translocation. In PRL-treated cells overexpressing
TRß1/RXR
, both Stat5 and TRß1 were coimmunoprecipitated,
indicating physical association of the two transcription factors. In
these cells, addition of T3 with ovine (o)PRL
decreased the amounts of total and tyrosine-phosphorylated Stat5 in the
cytoplasm compared with oPRL-treated cells. In the nucleus, no clear
difference was observed on Stat5 DNA-binding after treatment with PRL
and T3 vs. PRL alone in TRß1/RXR
transfected cells. However, antibodies directed against TRß1 lowered
Stat5-DNA binding and addition of the deacetylase inhibitor
trichostatin A (TSA) relieved T3 inhibition on Stat5
transcriptional activity. Thus, we postulated that the negative
cross-talk between TR and Stat5 on target genes could involve histone
deacetylase recruitment by liganded TRß1.
This article has been cited by other articles:
![]() |
M. B. Hapon, A. B Motta, M. Ezquer, M. Bonafede, and G. A Jahn Hypothyroidism prolongs corpus luteum function in the pregnant rat Reproduction, January 1, 2007; 133(1): 197 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
B Anguiano, R Rojas-Huidobro, G Delgado, and C Aceves Has the mammary gland a protective mechanism against overexposure to triiodothyronine during the peripartum period? The prolactin pulse down-regulates mammary type I deiodinase responsiveness to norepinephrine J. Endocrinol., November 1, 2004; 183(2): 267 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Litterst, S. Kliem, D. Marilley, and E. Pfitzner NCoA-1/SRC-1 Is an Essential Coactivator of STAT5 That Binds to the FDL Motif in the {alpha}-Helical Region of the STAT5 Transactivation Domain J. Biol. Chem., November 14, 2003; 278(46): 45340 - 45351. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Shipley and D. J. Waxman Down-Regulation of STAT5b Transcriptional Activity by Ligand-Activated Peroxisome Proliferator-Activated Receptor (PPAR) {alpha} and PPAR{gamma} Mol. Pharmacol., August 1, 2003; 64(2): 355 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. E. Timsit and D. S. Riddick Stimulation of Hepatic Signal Transducer and Activator of Transcription 5b by GH Is Not Altered by 3-Methylcholanthrene Endocrinology, September 1, 2002; 143(9): 3284 - 3294. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. R. Simon, J. Fortune, M. Iwahashi, and E. Sutherland Sexual dimorphic expression of ADH in rat liver: importance of the hypothalamic-pituitary-liver axis Am J Physiol Gastrointest Liver Physiol, September 1, 2002; 283(3): G646 - G655. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Bunn, J. A. Neidig, K. E. Freidinger, T. A. Stankiewicz, B. S. Weaver, J. McGrew, and L. A. Allison Nucleocytoplasmic Shuttling of the Thyroid Hormone Receptor {{alpha}} Mol. Endocrinol., April 1, 2001; 15(4): 512 - 533. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |